Hls Therapeutics Stock Performance
| HLTRF Stock | USD 2.60 0.17 7.00% |
On a scale of 0 to 100, HLS Therapeutics holds a performance score of 5. The company retains a Market Volatility (i.e., Beta) of 0.77, which attests to possible diversification benefits within a given portfolio. As returns on the market increase, HLS Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding HLS Therapeutics is expected to be smaller as well. Please check HLS Therapeutics' value at risk, as well as the relationship between the skewness and day typical price , to make a quick decision on whether HLS Therapeutics' current trending patterns will revert.
Risk-Adjusted Performance
5 of 100
Weak | Strong |
Modest
Compared to the overall equity markets, risk-adjusted returns on investments in HLS Therapeutics are ranked lower than 5 (%) of all global equities and portfolios over the last 90 days. Despite nearly fragile basic indicators, HLS Therapeutics reported solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 20.6 M | |
| Total Cashflows From Investing Activities | -4.5 M |
HLS |
HLS Therapeutics Relative Risk vs. Return Landscape
If you would invest 234.00 in HLS Therapeutics on August 29, 2024 and sell it today you would earn a total of 26.00 from holding HLS Therapeutics or generate 11.11% return on investment over 90 days. HLS Therapeutics is currently producing 0.2257% returns and takes up 3.4017% volatility of returns over 90 trading days. Put another way, 30% of traded pink sheets are less volatile than HLS, and 96% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
HLS Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for HLS Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as HLS Therapeutics, and traders can use it to determine the average amount a HLS Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0663
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | HLTRF | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 3.4 actual daily | 30 70% of assets are more volatile |
Expected Return
| 0.23 actual daily | 4 96% of assets have higher returns |
Risk-Adjusted Return
| 0.07 actual daily | 5 95% of assets perform better |
Based on monthly moving average HLS Therapeutics is performing at about 5% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of HLS Therapeutics by adding it to a well-diversified portfolio.
HLS Therapeutics Fundamentals Growth
HLS Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of HLS Therapeutics, and HLS Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on HLS Pink Sheet performance.
| Return On Equity | -0.14 | |||
| Return On Asset | -0.0276 | |||
| Profit Margin | (0.35) % | |||
| Operating Margin | (0.19) % | |||
| Current Valuation | 344.73 M | |||
| Shares Outstanding | 32.38 M | |||
| Price To Book | 1.86 X | |||
| Price To Sales | 4.41 X | |||
| Revenue | 60.01 M | |||
| EBITDA | 25.41 M | |||
| Cash And Equivalents | 21.16 M | |||
| Cash Per Share | 0.65 X | |||
| Total Debt | 84.13 M | |||
| Debt To Equity | 0.63 % | |||
| Book Value Per Share | 4.06 X | |||
| Cash Flow From Operations | 16.43 M | |||
| Earnings Per Share | (0.37) X | |||
| Total Asset | 275.9 M | |||
About HLS Therapeutics Performance
By analyzing HLS Therapeutics' fundamental ratios, stakeholders can gain valuable insights into HLS Therapeutics' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if HLS Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if HLS Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
HLS Therapeutics Inc., a specialty pharmaceutical company, acquires and commercializes pharmaceutical products in the specialty central nervous system and cardiovascular markets in Canada, the United States, and internationally. HLS Therapeutics Inc. was founded in 2018 and is headquartered in Etobicoke, Canada. Hls Therapeutics operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on OTC Exchange. It employs 92 people.Things to note about HLS Therapeutics performance evaluation
Checking the ongoing alerts about HLS Therapeutics for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for HLS Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| HLS Therapeutics had very high historical volatility over the last 90 days | |
| HLS Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the revenue of 60.01 M. Net Loss for the year was (13.12 M) with profit before overhead, payroll, taxes, and interest of 50.36 M. | |
| About 64.0% of the company shares are owned by institutional investors |
- Analyzing HLS Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether HLS Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining HLS Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating HLS Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of HLS Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of HLS Therapeutics' pink sheet. These opinions can provide insight into HLS Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for HLS Pink Sheet analysis
When running HLS Therapeutics' price analysis, check to measure HLS Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy HLS Therapeutics is operating at the current time. Most of HLS Therapeutics' value examination focuses on studying past and present price action to predict the probability of HLS Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move HLS Therapeutics' price. Additionally, you may evaluate how the addition of HLS Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk |